| Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics T Varma, JD Wallach, JE Miller, D Schnabel, JJ Skydel, AD Zhang, ... JAMA Network Open 4 (4), e217063-e217063, 2021 | 27 | 2021 |
| Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year MK Ellingson, X Shi, JJ Skydel, K Nyhan, R Lehman, JS Ross, JD Wallach BMJ open 11 (2), e047107, 2021 | 22 | 2021 |
| Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval JD Wallach, AD Zhang, JJ Skydel, VL Bartlett, SS Dhruva, ND Shah, ... JAMA network open 4 (11), e2133667-e2133667, 2021 | 20 | 2021 |
| Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019 MH Elliott, JJ Skydel, SS Dhruva, JS Ross, JD Wallach JAMA Internal Medicine 181 (2), 282-284, 2021 | 18 | 2021 |
| Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19 … O Moneer, G Daly, JJ Skydel, K Nyhan, P Lurie, JS Ross, JD Wallach bmj 377, 2022 | 17 | 2022 |
| US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018 JJ Skydel, AD Zhang, SS Dhruva, JS Ross, JD Wallach Clinical Trials, 2021 | 17 | 2021 |
| Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments JJ Skydel, AT Luxkaranayagam, SS Dhruva, JS Ross, JD Wallach JAMA network open 2 (5), e193410-e193410, 2019 | 17 | 2019 |
| Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 … JJ Skydel, AC Egilman, JD Wallach, R Ramachandran, R Gupta, JS Ross JAMA Health Forum 3 (5), e221158-e221158, 2022 | 9 | 2022 |
| Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive … M Mooghali, AP Mitchell, JJ Skydel, JS Ross, JD Wallach, ... BMJ Medicine 3 (1), 2024 | | 2024 |
| Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies JJ Skydel, R Ramachandran, S Suttiratana, JS Ross, CM Burns, ... The Journal of Rheumatology 51 (3), 320-322, 2024 | | 2024 |
| Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study. M Mooghali, JD Wallach, AP Mitchell, JJ Skydel, JS Ross, ... Journal of Clinical Oncology 41 (16_suppl), 1590-1590, 2023 | | 2023 |
Joshua D WallachAssistant Professor, Rollins School of Public HealthVerified email at emory.edu
